Goodwin Procter advised Prime Medicine™ on the deal. Prime Medicine™ announced its launch and funding rounds totaling $315 million. Prime Medicine is a biotechnology company founded to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Mirati Therapeutics, Inc. on the deal. Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced its collaboration and license agreement with Zai Lab Limited (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Mirati Therapeutics, Inc. on the deal. Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced its collaboration and license agreement with Zai Lab Limited (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vedere Bio II, Inc. on the deal. Vedere Bio II, Inc. announced its $77 million Series A financing. Vedere is developing next generation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vedere Bio II, Inc. on the deal. Vedere Bio II, Inc. announced its $77 million Series A financing. Vedere is developing next generation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised AbSci on the deal. AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The...
You must be a Standard 1 Year member to access this content.
